CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The ASCO 2025 Annual Meeting, is fast approaching and will be held from May 30 to June 3 in Chicago, Illinois -- This year the theme is of "Driving Knowledge to Action: Building a Better Future". This meeting will feature many CCTG trials and research so please see the list below to ensure you do not miss the oral presentations or poster presentations, showcasing the latest in CCTG research and clinical trial results.
The Steering Group is responsible for providing leadership for the Pharmacy Network.
As part of the CIHR commitment to promote capacity building in the Canadian cancer research landscape, the CIHR Institute of Cancer Research (CIHR-ICR), in partnership with the Canadian Cancer Research Alliance (CCRA), Canadian Cancer Society (CCS), Cancer Research Society (CRS), Ontario Institute for Cancer Research (OICR), and Terry Fox Research Institute (TFRI), has announced the open call for applications for its Early Career Researcher (ECR) Workshop.
IND.232, a Phase II Study of Durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer, has permanently closed.
MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.
